Potential of pre-operative MRI features in glioblastoma to predict for molecular stem cell subtype and patient overall survival.

Glioblastoma MGMT promoter methylation MRI Mesenchymal Proneural Stem cells

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 17 04 2023
revised: 31 07 2023
accepted: 14 08 2023
pubmed: 25 8 2023
medline: 25 8 2023
entrez: 24 8 2023
Statut: ppublish

Résumé

A molecular signature based on 10 mRNA abundances that characterizes the mesenchymal-to-proneural phenotype of glioblastoma stem(like) cells (GSCs) enriched in primary culture has been previously established. As this phenotype has been proposed to be prognostic for disease outcome the present study aims to identify features of the preoperative MR imaging that may predict the GSC phenotype of individual tumors. Molecular mesenchymal-to-proneural mRNA signatures and intrinsic radioresistance (SF A necrosis/tumor vector ratio and to a weaker extent the product of this ratio and the edema vector were identified to correlate with the mesenchymal-to-proneural mRNA signature and the SF Features of the preoperative MR images may reflect the molecular signature of the GSC population and might be used in the future as a prognostic factor and for treatment stratification especially in the MGMT promotor-unmethylated sub-cohort of glioblastoma patients.

Identifiants

pubmed: 37619660
pii: S0167-8140(23)89759-6
doi: 10.1016/j.radonc.2023.109865
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109865

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Franziska Eckert (F)

Department of Radiation Oncology, University of Tübingen, Germany; Medical University Vienna, Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Vienna, Austria. Electronic address: franziska.eckert@meduniwien.ac.at.

Katrin Ganser (K)

Department of Radiation Oncology, University of Tübingen, Germany.

Benjamin Bender (B)

Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany.

Jens Schittenhelm (J)

Department of Pathology and Neuropathology, University of Tübingen, Germany.

Marco Skardelly (M)

Department of Neurosurgery, University of Tübingen, Germany; Centre for Neurooncology, University of Tübingen, Germany.

Felix Behling (F)

Centre for Neurooncology, University of Tübingen, Germany.

Ghazaleh Tabatabai (G)

Centre for Neurooncology, University of Tübingen, Germany.

Elgin Hoffmann (E)

Department of Radiation Oncology, University of Tübingen, Germany.

Daniel Zips (D)

Department of Radiation Oncology, University of Tübingen, Germany; Department of Radiation Oncology, Charité Universitaetsmedizin Berlin, Germany.

Stephan M Huber (SM)

Department of Radiation Oncology, University of Tübingen, Germany.

Frank Paulsen (F)

Department of Radiation Oncology, University of Tübingen, Germany.

Classifications MeSH